Sera Prognostics (NASDAQ:SERA) CEO Sells $43,170.40 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,755 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $2.08, for a total value of $43,170.40. Following the completion of the sale, the chief executive officer directly owned 871,999 shares of the company’s stock, valued at approximately $1,813,757.92. This trade represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Down 3.1%

Shares of Sera Prognostics stock opened at $1.87 on Friday. The company has a market cap of $73.23 million, a PE ratio of -2.88 and a beta of 0.94. Sera Prognostics, Inc. has a 52 week low of $1.56 and a 52 week high of $4.09. The business has a 50 day moving average price of $2.02 and a 200-day moving average price of $2.54.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.58 EPS for the current year.

Analyst Ratings Changes

SERA has been the subject of several analyst reports. Craig Hallum began coverage on Sera Prognostics in a research note on Thursday, June 4th. They issued a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Institutional Trading of Sera Prognostics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Aberdeen Group plc increased its position in shares of Sera Prognostics by 2.3% during the third quarter. Aberdeen Group plc now owns 2,279,699 shares of the company’s stock valued at $6,976,000 after acquiring an additional 52,332 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sera Prognostics by 4.6% during the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after acquiring an additional 54,008 shares during the last quarter. Citadel Advisors LLC increased its position in shares of Sera Prognostics by 1.9% during the third quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after acquiring an additional 12,439 shares during the last quarter. Captrust Financial Advisors increased its position in shares of Sera Prognostics by 20.0% during the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after acquiring an additional 100,366 shares during the last quarter. Finally, Segall Bryant & Hamill LLC purchased a new stake in shares of Sera Prognostics during the first quarter valued at approximately $193,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.